← Eichor
Study identifier: NCT06582199 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

Condition: Alzheimer Disease  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants244
Who can joinAll sexes, 50 Years to 90 Years
Healthy volunteersNo

About this study

BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.

This description comes directly from the study's public registry record.

Talk to the study team

Olivier HANON, MD, PhD  ·  + 1 44 08 33 81  ·  olivier.hanon@aphp.fr

Valérie PLENCE, MSc  ·  +33 1 54 41 11 78  ·  valerie.plence@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hôpital CochinParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06582199